Transfusion-related acute lung injury (TRALI) is a life-threatening complication of transfusion of blood products. A case of severe TRALI secondary to infusion of fresh frozen plasma in the intensive care unit is discussed. Additionally, the aetiology and pathogenesis of this relatively under-diagnosed and under-reported clinical entity is reviewed. It is our conclusion that proper diagnosis and reporting is necessary for prompt and appropriate treatment of the patient and to prevent additional reactions in other patients.
Transfusion-related acute lung injury (TRALI) is a syndrome characterized by development of dyspnea, hypoxaemia, fever, hypotension and bilateral pulmonary oedema secondary to transfusion of blood products 1, 2 . The severity may range from mild disease to severe life-threatening emergency 2 . Although TRALI is a well-known clinical entity among health professionals dealing with transfusion medicine, it has received limited exposure among anaesthesia providers and critical care physicians. Here we report a case of severe life-threatening TRALI following transfusion of fresh frozen plasma (FFP).
CASE HISTORY
A 17-year-old male weighing 65 kg presented to our hospital following gunshot injury to the left groin. He underwent emergency exploration of the wound under general endotracheal anaesthesia. Intra-operatively, injury to the left superficial femoral vein and artery were discovered. He underwent repair of the left superficial femoral artery with polytetraflouroethylene graft and ligation of the left superficial femoral vein. During surgery he was transfused ten units of packed red blood cells, six units of FFP and six units of random donor platelets.
Postoperatively he was transferred to the surgical intensive care unit fully awake, oriented, and in no respiratory distress. He had stable haemodynamics. Coagulation studies revealed a prothrombin time of 40 s and partial thromboplastin time greater than 150 s. Four units of FFP were transfused over a period of one hour. While receiving the last unit of FFP, the patient became severely diaphoretic and agitated with sudden onset of severe dyspnoea. He started expectorating copious pink frothy secretions and his oxygen saturation dropped to <70% while breathing 100% oxygen through a non-rebreathing mask. He was tachycardic (130 beats per min), and hypertensive (210/98 mmHg). He was immediately intubated and placed on intermittent positive pressure ventilation with positive end-expiratory pressure of 12 cm H 2 O. Arterial-blood-gas analysis revealed a P a O 2 = 34 mmHg on 100% inspired oxygen concentration. His chest X-ray was consistent with bilateral massive pulmonary oedema. A transthoracic echocardiogram demonstrated a hyperdynamic myocardium with normal biventricular function and no valvular abnormality. A pulmonary artery catheter was placed, which showed filling pressures consistent with noncardiogenic pulmonary oedema, with a cardiac output of 12 l/min, a pulmonary artery occlusion pressure of 10 mmHg, and a right atrial pressure of 3 mmHg. A pulmonary arteriogram was negative for pulmonary embolism. An urgent consultation with transfusion medicine was requested and a working diagnosis of TRALI was entertained. The FFP samples were sent to the laboratory to screen for human leukocyte anti-gen antibodies. Subsequently, the results obtained indicated that three of the four FFP units had significant load of human leukocyte antigen antibodies. After 48 hours of mechanical ventilation the patient was extubated. There was no further complication.
DISCUSSION
TRALI is the third leading cause of transfusionrelated mortality with a case-specific mortality of 5 to 10% 2,3 . Diagnosis may not be immediately obvious, and the signs and symptoms could easily be attributed to other systemic causes such as fluid overload, pneumonia, congestive heart failure, aspiration and adult respiratory distress syndrome.
In our patient the diagnosis of TRALI was entertained only after all other causes of acute pulmonary oedema and severe hypoxaemia were ruled out, since most of the clinicians involved in the care of the patient were unfortunately unaware of TRALI as a clinical entity. Cardiac causes of acute pulmonary oedema appeared unlikely in the presence of normal serum cardiac enzymes, normal electrocardiogram and low pulmonary artery occlusion pressure. The possibility of intravascular volume overload secondary to massive transfusion in the perioperative period precipitating pulmonary oedema was excluded since the patient had normal to low right atrial pressure. Massive bilateral pulmonary oedema in the presence of low right atrial pressure and pulmonary artery occlusion pressure was clearly indicative of severe acute lung injury. The temporal relation of the development of acute respiratory distress while receiving FFP prompted us to investigate the possibility of TRALI. The hypertension, tachycardia and diaphoresis we considered may have been secondary to overwhelming sympathetic discharge in our patient, secondary to severe hypoxaemia. Our patient did not display two of the three classical signs of TRALI, i.e. fever and hypotension.
TRALI classically has been attributed to the interaction between anti-granulocyte antibodies (usually of donor origin) and granulocytes (usually of recipient origin) 4 . This theory is supported by the finding of anti-granulocyte antibodies in the donor and recipient serums following episodes of clinically significant TRALI 5 . A similar form of acute lung injury has been demonstrated after transfusion of antigranulocyte antibodies into laboratory animals 6 . In one instance, postmortem examination within hours of developing TRALI demonstrated granulocyte aggregates within the alveolar capillaries associated with endothelial injury 7 . However, a significant difference exists between the incidence of TRALI and the prevalence of anti-granulocyte antibodies in the donors. More recently, HLA class I antibodies, HLA class II antibodies, and various biologically active lipids present in the donor plasma have been implicated in the pathogenesis of TRALI. Reports indicate that all plasma containing blood components i.e. packed red blood cells, platelets, FFP and cryoprecipitates can cause TRALI 8 . In addition, intravenous immunoglobulins and bioactive substances released during the storage of blood products have also been suggested to play a role in the development 9, 10 . Currently it is believed that TRALI is the end result of a combination of these patient and blood-product related factors leading to an increase in permeability at the alveolar capillary interface in the recipient's lungs.
Some recipient specific factors have also been suggested in the pathogenesis of TRALI. It has been proposed that the patient first must have a predisposing risk factor and then receive plasma containing either anti-leukocyte antibody or biologically active lipid 11, 12 . The predisposing risk factors thus far identified include ongoing infection, massive blood transfusion, recent surgery/trauma, and cytokine administration. Our patient had had recent surgery/trauma, and had received massive blood transfusion intraoperatively, which may have functioned as priming factors.
The possibility of TRALI should always be considered while treating patients who develop dyspnoea, hypoxaemia, and bilateral pulmonary infiltrates during or within a few hours following transfusion of any blood product or plasma derivative containing plasma. Once other potential causes have been excluded, the blood transfusion service should be alerted to the possibility of TRALI. The finding of granulocyte, leukoagglutinating or lymphocytotoxic antibodies in the serum of either the donor or the recipient is considered diagnostic of TRALI. However, since the sensitivities of these tests in diagnosing TRALI are unknown, the diagnosis of TRALI remains a clinical diagnosis of exclusion. The treatment of TRALI is supportive, and in up to 70% of reported instances, mechanical ventilation with positive endexpiratory pressure and high concentration of inspired oxygen were required. Further management is guided by the same principles used in the management of patients with acute respiratory distress syndrome.
The incidence of TRALI has been estimated at 1:5000 transfusions 13 . However, this may be an underestimate due to a lack of awareness among physicians leading to failure to diagnose and report occurrence of TRALI. In a recent clinical look back investiga-tion of a case of death due to TRALI, Kopko et al concluded that clinical education and awareness of this often overlooked entity are imperative for appropriate diagnosis and treatment 14 .
